Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and respiratory infections; and Phlegm-Heat Clearing Capsules to clear heat, resolve phlegm, and detoxifying. It also provides liver-protecting products, including Thiopronine for injection and Thiopronine enteric-coated tablets. In addition, the company provides Astragalus and Ginseng Capsules for the treatment of cardiovascular and cerebrovascular diseases. Further, it offers diclofenac sodium enteric-coated tablets; artificial bezoar metronidazole capsules; Mai'an granules; Loquat cough granules that clears the lungs, relieves cough, and reduces phlegm; compound danshen tablets; Tongmai granules to promote blood circulation and unblocks meridians; pediatric pharyngeal granules; stroke rejuvenation pills; and Xiao Chai Hu granules which relieves exterior syndromes, clears heat, soothes the liver, and harmonizes the stomach. Further, the company provides Alopecia areata; Bear bile drops that clears heat, calms the liver, and improves eyesight, as well as used for infantile convulsions and sore throat; and Shanhaidan capsules. Shanghai Kaibao Pharmaceutical CO.,Ltd was founded in 2000 and is based in Shanghai, China.
Research context
Shanghai Kaibao Pharmaceutical CO.,Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Shanghai Kaibao Pharmaceutical CO.,Ltd is currently in a long term uptrend where the price is trading 8.7% above its 200 day moving average.
From a valuation standpoint, the stock is 55.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.3.
Shanghai Kaibao Pharmaceutical CO.,Ltd's total revenue sank by 37.5% to $172M since the same quarter in the previous year.
Its net income has dropped by 47.9% to $29M since the same quarter in the previous year.
Finally, its free cash flow grew by 106.8% to $94M since the same quarter in the previous year.
Based on the above factors, Shanghai Kaibao Pharmaceutical CO.,Ltd gets an overall score of 3/5.